Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660424 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
A Phase 2 study of Osteoarthritis, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 12
- Study locations
NCT02660424: Completed Phase 2 study of Osteoarthritis, sponsored by Vertex Pharmaceuticals Incorporated.
NCT02660424 is a Phase 2 study of Osteoarthritis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 124 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660424, a Phase 2 study of Osteoarthritis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 12
- Study locations
Study Summary
The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-150
Study Locations (12)
California
- - San Diego
Florida
- - West Palm Beach
Georgia
- - Marietta
Indiana
- - Valparaiso
Kansas
- - Wichita
Michigan
- - Bay City
Nevada
- - Las Vegas
New York
- - Hartsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT02660424 record still lists
NCT02660424 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02660424 lists 12 locations in 12 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT02660424 about?
NCT02660424 is a clinical study titled "A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee". The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain
What is the current status of trial NCT02660424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-12. Estimated completion is 2016-09.
What conditions does trial NCT02660424 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT02660424?
The interventions under investigation include: Placebo (DRUG), VX-150 (DRUG).
Who is sponsoring clinical trial NCT02660424?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02660424 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02660424's enrollment target sits among peer trials
124 80th of 135 higher than 56 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia